Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Avalon GloboCare Corp. (ALBT)
Freehold, NJ, US
Avalon GloboCare Corp., along with its affiliated entities, manages and holds commercial real estate assets across both the United States and China. The company's service portfolio encompasses medical consulting, offering diverse solutions such as conducting research studies, delivering executive education, disseminating daily online briefings for executives, providing customized expert advice, and supplying management and consulting expertise, particularly in the fields of immunotherapy and in facilitating second opinions or referrals. Key therapeutic candidates include AVA-001, an anti-CD19 CAR-T therapy, which has successfully completed its initial human clinical trial for B-cell lymphoblastic leukemia that has recurred or is resistant to treatment (R/R). Another promising candidate, AVA-011, also a CAR-T cell therapy, has advanced through preclinical laboratory evaluations and is currently in the IND-enabling process development phase to produce cGMP-grade cells. The company is additionally engaged in the development of an RNA-based FASH-CARTM cell therapy platform. Furthermore, Avalon GloboCare is developing ACTEX, its proprietary clinical-grade, tissue-specific exosome. It collaborates with the Massachusetts Institute of Technology (MIT) to identify therapeutic and diagnostic targets using QTY-code protein design technology, which includes leveraging this technology to create a hemofiltration device for treating Cytokine Storm. The firm also partners with Arbele Limited for the co-development of advanced, transposon-based CAR-T, CAR-NK, and various other multi-target immune effector cell therapies. A strategic alliance with the University of Natural Resources and Life Sciences in Vienna, Austria, aims to develop an S-layer vaccine against SARS-CoV-2 (the virus responsible for COVID-19), designed for intranasal or oral delivery. Beyond these initiatives, the company is progressing with Avalon Cell and Avalon Rehab, and actively advocates for standardization within the exosome industry. Its corporate headquarters are situated in Freehold, New Jersey.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.68% | -1.91% | -10.30% | -55.76% | -78.84% | -67.56% | -89.73% | -98.58% | -99.72% | -99.63% | -99.63% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Real Estate - Services: +11.2%-100.0% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Real Estate - Services: +25.9%+33.2% ★ Q1'26: +65.0% (vs Q1'25)
-
FCF margin FCF growth · Real Estate - Services: +32.2%—
-
EBIT margin Real Estate - Services: +23.7%—
-
ROIC Real Estate - Services: +4.3%-176.0% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Real Estate - Services: +0.0%+242.8% Q1'26: +451.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Real Estate - Services: 1.88×0.00× Q1'26: -0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|---|
| Revenue |
1.20M
est: 1.20M (+0.0%)
|
1.26M
est: 2.40M (-47.8%)
|
1.33M
est: 3.61M (-63.0%)
|
| EBITDA |
-7.89M
est: -1.20M (-556.2%)
|
-15.03M
est: -2.40M (-524.9%)
|
-5.17M
est: -3.61M (-43.2%)
|
| EBIT |
-8.35M
est: -1.20M (-595.0%)
|
-15.36M
est: -2.40M (-538.7%)
|
-5.47M
est: -3.61M (-51.6%)
|
| Net Income |
-11.93M
|
-16.71M
|
-7.90M
|
| SGA |
6.98M
|
7.31M
|
4.35M
|
| EPS |
-1.36
|
-1.59
|
-8.44
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 20.0K | 0.05% |
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-12 | Mathews Michael | Director | A-Award | A | Series E Non-Voting Convertible Preferred Stock | 1,365 | 1.50 | 2.0K | 1,365 | D | ↗ |
| 2023-01-09 | Felix Lourdes | Director | — | D | Stock Option | 7,803 | 4.01 | 31.3K | 0 | — | ↗ |
| 2023-01-01 | Troy Tevi | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 5.20 | 41.6K | 8,000 | — | ↗ |
| 2023-01-01 | Tauzin W J | Director | A-Award | A | Stock Option (right to buy) | 4,000 | 5.20 | 20.8K | 4,000 | — | ↗ |
| 2023-01-01 | Stilley William B. III | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 5.20 | 41.6K | 8,000 | — | ↗ |
| 2023-01-01 | Sanders Steven Andrew | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 5.20 | 41.6K | 8,000 | — | ↗ |
| 2022-11-01 | Tauzin W J | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 4.30 | 34.4K | 8,000 | — | ↗ |
| 2022-08-05 | Lu Wenzhao | Director / 10% Owner | A-Award | A | Common Stock, $.0001 par value | 448,718 | 0.78 | 350.0K | 33,192,708 | — | ↗ |
| 2022-07-25 | Lu Wenzhao | Director / 10% Owner | A-Award | A | Common Stock, $.0001 par value | 4,442,989 | 0.65 | 2.89M | 32,742,989 | — | ↗ |
| 2022-07-18 | Lu Wenzhao | Director / 10% Owner | A-Award | A | Common Stock, $.0001 par value | 4,440,390 | 0.65 | 2.89M | 32,740,390 | — | ↗ |
| 2022-05-01 | Tauzin W J | Director | A-Award | A | Stock Option right to buy) | 8,000 | 5.30 | 42.4K | 8,000 | — | ↗ |
| 2022-01-01 | Troy Tevi | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 8.20 | 65.6K | 8,000 | — | ↗ |
| 2022-01-01 | Tauzin W J | Director | A-Award | A | Stock Option (right to buy) | 4,000 | 8.20 | 32.8K | 4,000 | — | ↗ |
| 2022-01-01 | Stilley William B. III | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 8.20 | 65.6K | 8,000 | — | ↗ |
| 2022-01-01 | Sanders Steven Andrew | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 8.20 | 65.6K | 8,000 | — | ↗ |
| 2021-12-21 | Lu Wenzhao | Director / 10% Owner | A-Award | A | Common Stock, $.0001 par value | 2,400,000 | 1.25 | 3.00M | 28,300,000 | — | ↗ |
| 2021-11-01 | Tauzin W J | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 10.30 | 82.4K | 8,000 | — | ↗ |
| 2021-05-01 | Tauzin W J | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 10.20 | 81.6K | 8,000 | — | ↗ |
| 2021-01-01 | Troy Tevi | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 11.20 | 89.6K | 8,000 | — | ↗ |
| 2021-01-01 | Tauzin W J | Director | A-Award | A | Stock Option (right to buy) | 4,000 | 11.20 | 44.8K | 4,000 | — | ↗ |
| 2021-01-01 | Stilley William B. III | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 11.20 | 89.6K | 8,000 | — | ↗ |
| 2021-01-01 | Sanders Steven Andrew | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 11.20 | 89.6K | 8,000 | — | ↗ |
| 2020-04-01 | Lu Wenzhao | Director / 10% Owner | P-Purchase | A | Common Stock, $.0001 par value | 645,161 | 1.55 | 1,000.0K | 2,645,161 | — | ↗ |
| 2020-02-25 | Troy Tevi | Director | A-Award | A | Stock Option | 80,000 | 1.52 | 121.6K | 80,000 | — | ↗ |
| 2020-02-25 | Stilley William B. III | Director | A-Award | A | Stock Option | 80,000 | 1.52 | 121.6K | 80,000 | — | ↗ |
| 2020-02-25 | Sanders Steven Andrew | Director | A-Award | A | Stock Option | 80,000 | 1.52 | 121.6K | 80,000 | — | ↗ |
| 2020-02-25 | Lu Yancen | Director | A-Award | A | Stock Option | 80,000 | 1.52 | 121.6K | 80,000 | — | ↗ |
| 2020-02-25 | Li Yue Charles | Director | A-Award | A | Stock Option | 80,000 | 1.52 | 121.6K | 80,000 | — | ↗ |
| 2020-02-25 | Li Meng | Director / Officer | A-Award | A | Stock Options | 300,000 | 1.52 | 456.0K | 300,000 | — | ↗ |
| 2020-02-20 | Jin David | Director / Officer | A-Award | A | Stock Options | 400,000 | 1.52 | 608.0K | 400,000 | — | ↗ |
| 2020-02-20 | Ingargiola Luisa | Officer | A-Award | A | Stock Option | 400,000 | 1.52 | 608.0K | 400,000 | — | ↗ |
| 2019-06-07 | Lu Wenzhao | Director / 10% Owner | P-Purchase | A | Common Stock, $.0001 par value | 15,000 | 1.84 | 27.6K | 25,936,000 | — | ↗ |
| 2019-06-06 | Lu Wenzhao | Director / 10% Owner | P-Purchase | A | Common Stock, $.0001 par value | 21,000 | 2.03 | 42.6K | 25,921,000 | — | ↗ |
| 2019-04-18 | Lu Wenzhao | Director / 10% Owner | P-Purchase | D | Common Stock, $.0001 par value | 2,000,000 | 1.00 | 2.00M | 2,000,000 | — | ↗ |
| 2019-04-15 | Li Yue Charles | Director | — | D | Stock Option | 30,000 | 4.76 | 142.8K | 0 | — | ↗ |
| 2019-04-05 | Li Yue Charles | Director | — | D | Stock Option | 30,000 | 4.76 | 142.8K | 0 | — | ↗ |
| 2019-04-05 | Li Meng | Director / Officer | A-Award | A | Stock Option | 30,000 | 4.76 | 142.8K | 30,000 | — | ↗ |
| 2019-01-03 | Lu Wenzhao | Director / 10% Owner | A-Award | A | Stock Options | 1,500,000 | 2.00 | 3.00M | 1,500,000 | — | ↗ |
| 2018-07-30 | Sanders Steven Andrew | Director | — | D | Stock Option | 20,000 | 2.80 | 56.0K | 0 | — | ↗ |
| 2018-07-05 | Stilley William B. III | Director | — | D | Stock Option | 20,000 | 2.30 | 46.0K | 0 | — | ↗ |
| 2018-06-04 | Troy Tevi | Director | — | D | Stock Option | 20,000 | 2.30 | 46.0K | 0 | — | ↗ |
| 2017-12-15 | Sukel Steven Philip | Director | P-Purchase | A | Common Stock, $.0001 par value | 100 | 2.60 | 260.00 | 217,615 | — | ↗ |
| 2017-11-20 | Sukel Steven Philip | Director | P-Purchase | A | Common Stock, $.0001 par value | 300 | 1.98 | 594.00 | 214,415 | — | ↗ |
| 2017-11-01 | Tauzin W J | Director | — | D | Stock Option | 50,000 | 1.00 | 50.0K | 0 | — | ↗ |
| 2017-04-28 | Sukel Steven Philip | Director | — | D | Stock Option | 30,000 | 1.49 | 44.7K | 0 | — | ↗ |
| 2017-04-28 | Lu Yancen | Director | — | D | Stock Option | 30,000 | 1.49 | 44.7K | 0 | — | ↗ |
| 2017-04-20 | Lu Yancen | Director | — | D | Stock Option | 30,000 | 1.49 | 44.7K | 0 | — | ↗ |
| 2017-04-20 | Lu Wenzhao | Director | S-Sale | D | Common Stock, $.0001 par value | 5,000,000 | 0.50 | 2.50M | 25,900,000 | — | ↗ |
| 2017-04-01 | Sukel Steven Philip | Director | P-Purchase | A | Common Stock, $.0001 par value | 200,000 | 1.50 | 300.0K | 200,000 | — | ↗ |
| 2017-02-21 | Ingargiola Luisa | Officer | — | D | Stock Option | 2,000,000 | 0.50 | 1.00M | 0 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Luisa Ingargiola | Chief Financial Officer | 525.0K | female |
| Meng Li | Interim CEO, COO & Secretary | 191.7K | female |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALBT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
